FDx Advisors Inc. Has $3.80 Million Stake in Novartis AG (NVS)

FDx Advisors Inc. lifted its position in shares of Novartis AG (NYSE:NVS) by 18.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,307 shares of the company’s stock after purchasing an additional 7,035 shares during the quarter. FDx Advisors Inc.’s holdings in Novartis were worth $3,804,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of NVS. Parnassus Investments CA grew its stake in Novartis by 18.5% in the 3rd quarter. Parnassus Investments CA now owns 9,447,817 shares of the company’s stock valued at $811,095,000 after acquiring an additional 1,477,168 shares during the period. BlackRock Inc. grew its stake in Novartis by 8.2% in the 4th quarter. BlackRock Inc. now owns 4,015,562 shares of the company’s stock valued at $337,146,000 after acquiring an additional 305,221 shares during the period. Boston Partners grew its stake in Novartis by 14.9% in the 3rd quarter. Boston Partners now owns 1,857,435 shares of the company’s stock valued at $159,461,000 after acquiring an additional 240,573 shares during the period. Amundi Pioneer Asset Management Inc. grew its stake in Novartis by 228.8% in the 3rd quarter. Amundi Pioneer Asset Management Inc. now owns 317,300 shares of the company’s stock valued at $27,240,000 after acquiring an additional 220,800 shares during the period. Finally, Fisher Asset Management LLC grew its stake in Novartis by 2.8% in the 4th quarter. Fisher Asset Management LLC now owns 6,816,625 shares of the company’s stock valued at $572,324,000 after acquiring an additional 183,641 shares during the period. 10.96% of the stock is currently owned by institutional investors and hedge funds.

Novartis AG (NYSE:NVS) opened at $85.37 on Wednesday. The company has a quick ratio of 0.91, a current ratio of 1.21 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $201,410.11, a price-to-earnings ratio of 17.99, a price-to-earnings-growth ratio of 2.02 and a beta of 0.73. Novartis AG has a fifty-two week low of $72.67 and a fifty-two week high of $94.19.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.04. The company had revenue of $12.92 billion for the quarter, compared to analyst estimates of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 EPS. equities research analysts forecast that Novartis AG will post 5.36 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research note on Thursday, January 18th. UBS Group reissued a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Zacks Investment Research cut shares of Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Nord/LB reissued a “neutral” rating on shares of Novartis in a research note on Tuesday, January 2nd. Finally, Bank of America cut shares of Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, December 6th. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $85.32.

COPYRIGHT VIOLATION NOTICE: This piece was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/02/21/fdx-advisors-inc-has-3-80-million-stake-in-novartis-ag-nvs.html.

About Novartis

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply